Advertisement
UK markets close in 5 hours 46 minutes
  • FTSE 100

    8,357.41
    +3.36 (+0.04%)
     
  • FTSE 250

    20,477.24
    -14.75 (-0.07%)
     
  • AIM

    781.44
    +1.61 (+0.21%)
     
  • GBP/EUR

    1.1634
    +0.0012 (+0.10%)
     
  • GBP/USD

    1.2484
    -0.0013 (-0.10%)
     
  • Bitcoin GBP

    48,896.33
    -894.14 (-1.80%)
     
  • CMC Crypto 200

    1,318.01
    +17.92 (+1.38%)
     
  • S&P 500

    5,187.67
    -0.03 (-0.00%)
     
  • DOW

    39,056.39
    +172.13 (+0.44%)
     
  • CRUDE OIL

    79.40
    +0.41 (+0.52%)
     
  • GOLD FUTURES

    2,315.60
    -6.70 (-0.29%)
     
  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     
  • HANG SENG

    18,537.81
    +223.95 (+1.22%)
     
  • DAX

    18,539.96
    +41.58 (+0.22%)
     
  • CAC 40

    8,115.35
    -16.06 (-0.20%)
     

Ozempic Could Be Potential Driver for Novo Nordisk in 2018

Ozempic Could Be Potential Driver for Novo Nordisk in 2018

In December 2017, the FDA approved Novo Nordisk’s (NVO) Ozempic as an add-on to diet and exercise for the management of blood sugar levels in adult individuals with Type 2 diabetes.